Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.

Abstract

5576Background: OS is considered the gold standard endpoint for controlled clinical trials but it requires extended follow-up (median OS > 40 months for first line therapy) and large sample sizes. ...